Lung Cancer
Conditions
Keywords
recurrent non-small cell lung cancer, stage IIIB non-small cell lung cancer, stage IV non-small cell lung cancer, stage IIIA non-small cell lung cancer
Brief summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Giving erlotinib together with stereotactic body radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving erlotinib together with stereotactic body radiation therapy works in treating patients with locally advanced or metastatic non-small cell lung cancer.
Detailed description
OBJECTIVES: Primary * To evaluate the effect of erlotinib and stereotactic body radiotherapy on 6-month progression-free survival of patients with locally advanced or metastatic non-small cell lung cancer. Secondary * To describe the actuarial rate of in-field local control and out-of-field disease progression in patients treated with this regimen. * To evaluate the safety of this regimen in these patients. * To evaluate overall survival of patients treated with this regimen. * To evaluate the duration of erlotinib usage and time to initiation of third-line systemic therapy (chemotherapy or biologic agent) in these patients. OUTLINE: This is a multicenter study. Patients receive oral erlotinib hydrochloride once daily in the absence of disease progression or unacceptable toxicity. Beginning 1-4 weeks after the initiation of erlotinib hydrochloride, patients undergo stereotactic body radiotherapy. After completion of study treatment, patients are followed every 3 months.
Interventions
DRUGErlotinib
Erlotinib is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.
RADIATIONSBRT
SBRT is a treatment method to deliver a high dose of radiation to the target, utilizing either a single dose or a small number of fractions with a high degree of precision within the body
Sponsors
University of Texas Southwestern Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This study is a single arm phase II pilot trial. Patients enrolled on the trial will have been receiving or will begin to receive erlotinib at standard doses (150 mg po per day). SBRT will commence within 4 weeks of the initiation of erlotinib. Maintenance erlotinib will continue until disease progression uncontrollable by SBRT, intolerable toxicity, or death.
Eligibility
Sex/Gender
ALL
Age
18 Years to 120 Years
Healthy volunteers
No
Inclusion criteria
Patients must meet all of the following inclusion criteria to be eligible for participation in this study: 1. Patients must have biopsy proven NSCLC that is locally advanced or metastatic. 2. Patients must have had failure of at least one prior chemotherapy regimen. 3. Patients must not have started erlotinib therapy more than 4 weeks prior to the initiation of SBRT. 4. Age ≥ 18 years 5. Patients must have measurable disease at baseline. 6. Patients can have up to only 6 discrete active extracranial lesions (≤3 in the liver and ≤3 in the lung) identified by PET scan and also seen on correlative plain film, CT scan, or MRI within 8 weeks prior to the initiation of SBRT. 1. For patients who have received prior radiotherapy to the primary site in the lung, residual PET activity is difficult to interpret and will not be considered a site of active disease if the CT appearance is stable or improved over an interval of at least three months 2. Patients who previously received radiotherapy to the primary site will be ineligible if there is CT evidence of disease progression within the past 3 months. 3. Patients with previously un-irradiated primary sites will be potentially eligible, but special considerations apply (section 4.3.2). 4. Up to 2 contiguous vertebral metastases will be considered a single site of disease. 7. Patients must have a KPS \>60 8. AST, ALT & Alkaline phosphates must be ≤ 2.5X the upper limit of normal. Total bilirubin must be within the limit of normal. 9. Patients should have adequate bone marrow function as defined by peripheral granulocyte count of ≥1500/mm³. 10. Patients should have adequate renal function (serum creatinine ≤1.5 times the ULN). 11. Females of childbearing potential should have a negative pregnancy test. 12. Patients who would be receiving SBRT for lung tumors who are known or suspected by the treating radiation oncologist to have compromised lung function must have a documented forced expiratory volume in 1 second (FEV1) ≥ 1L. 13. Patients must provide verbal and written informed consent to participate in the study. 14. Total bilirubin: within normal institutional limits
Exclusion criteria
Patients who meet any of the following
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 6 Month Progression-Free Survival | 6 months | For liver lesions treated with SBRT, RECIST (Response Evaluation Criteria in Solid Tumors) criteria will be used for evaluation of progression. Progression (PD) is at least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Evaluation of lung lesions at any time after SBRT is difficult in view of the expected fibrotic reaction. Bone lesions seen only on PET are also not well scored by RECIST criteria and will not be evaluated in that manner. In this study progressive disease (PD) will be defined as residual increased metabolic PET scan in combination with expanded parenchymal opacity that retains mass-like discrete borders and extends outside the volume of lung that received at least 18 Gy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Without Serious Adverse Events Related to Radiation | 3 years | Common Terminology Criteria for Adverse Events v4.03 (CTCAE) is used as the standard classification and severity grading scale for adverse events |
| Overall Survival | up to 5 years | evaluate overall survival after SBRT in combination with erlotinib |
| In-field Local Control | 9 months | In-field local control is defined as number of treated lesions that did not grow in size or increase in metabolic activity. |
| Out-of-field Disease Progression | 9 months | Number of Participants with Disease Progression Outside the Radiation treated field at 9 Months |
| Progression-free Survival | up to 5 years | For liver lesions treated with SBRT, RECIST (Response Evaluation Criteria in Solid Tumors) criteria will be used for evaluation of progression. Progression (PD) is at least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Evaluation of lung lesions at any time after SBRT is difficult in view of the expected fibrotic reaction. Bone lesions seen only on PET are also not well scored by RECIST criteria and will not be evaluated in that manner. In this study progressive disease (PD) will be defined as residual increased metabolic PET scan in combination with expanded parenchymal opacity that retains mass-like discrete borders and extends outside the volume of lung that received at least 18 Gy. |
| Duration of Erlotinib Use and Time to Initiation of Third-line Systemic Therapy | 3 years | To evaluate the duration of erlotinib usage and time to initiation of third line systemic agent (chemotherapy or biologic agent) |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| SBRT in Combination With Erlotinib Patients enrolled on the trial will have been receiving or will begin to receive erlotinib at standard doses (150 mg po per day). SBRT will commence within 4 weeks of the initiation of erlotinib
Erlotinib: Erlotinib is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.
SBRT: SBRT is a treatment method to deliver a high dose of radiation to the target, utilizing either a single dose or a small number of fractions with a high degree of precision within the body | 24 |
| Total | 24 |
Baseline characteristics
| Characteristic | SBRT in Combination With Erlotinib |
|---|---|
| Age, Continuous | 67 years |
| Region of Enrollment United States | 24 Participants |
| Sex: Female, Male Female | 11 Participants |
| Sex: Female, Male Male | 13 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 13 / 24 |
| other Total, other adverse events | 0 / 24 |
| serious Total, serious adverse events | 5 / 24 |
Outcome results
Primary
6 Month Progression-Free Survival
For liver lesions treated with SBRT, RECIST (Response Evaluation Criteria in Solid Tumors) criteria will be used for evaluation of progression. Progression (PD) is at least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Evaluation of lung lesions at any time after SBRT is difficult in view of the expected fibrotic reaction. Bone lesions seen only on PET are also not well scored by RECIST criteria and will not be evaluated in that manner. In this study progressive disease (PD) will be defined as residual increased metabolic PET scan in combination with expanded parenchymal opacity that retains mass-like discrete borders and extends outside the volume of lung that received at least 18 Gy.
Time frame: 6 months
Population: Twenty-four patients with stage IV Non-small-Cell Lung Caner with six or fewer sites of disease after progressing through first-line or subsequent systemic therapy were enrolled on the study.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| SBRT Combined With Erlotinib | 6 Month Progression-Free Survival | 69 percentage of participants |
Secondary
Duration of Erlotinib Use and Time to Initiation of Third-line Systemic Therapy
To evaluate the duration of erlotinib usage and time to initiation of third line systemic agent (chemotherapy or biologic agent)
Time frame: 3 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| SBRT Combined With Erlotinib | Duration of Erlotinib Use and Time to Initiation of Third-line Systemic Therapy | 183 days |
Secondary
In-field Local Control
In-field local control is defined as number of treated lesions that did not grow in size or increase in metabolic activity.
Time frame: 9 months
Population: 21 out of 24 patients were evaluable with baseline and minimum 3-month follow-up CT based imaging. The other three patients died or had not otherwise reached this window for evaluation.
| Arm | Measure | Value (COUNT_OF_UNITS) |
|---|---|---|
| SBRT Combined With Erlotinib | In-field Local Control | 44 lesions treated with SBRT |
Secondary
Number of Participants Without Serious Adverse Events Related to Radiation
Common Terminology Criteria for Adverse Events v4.03 (CTCAE) is used as the standard classification and severity grading scale for adverse events
Time frame: 3 years
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| SBRT Combined With Erlotinib | Number of Participants Without Serious Adverse Events Related to Radiation | 22 Participants |
Secondary
Out-of-field Disease Progression
Number of Participants with Disease Progression Outside the Radiation treated field at 9 Months
Time frame: 9 months
Population: The other three patients died or had not otherwise reached this window for evaluation.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| SBRT Combined With Erlotinib | Out-of-field Disease Progression | 10 Participants |
Secondary
Overall Survival
evaluate overall survival after SBRT in combination with erlotinib
Time frame: up to 5 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| SBRT Combined With Erlotinib | Overall Survival | 20.4 months |
Secondary
Progression-free Survival
For liver lesions treated with SBRT, RECIST (Response Evaluation Criteria in Solid Tumors) criteria will be used for evaluation of progression. Progression (PD) is at least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Evaluation of lung lesions at any time after SBRT is difficult in view of the expected fibrotic reaction. Bone lesions seen only on PET are also not well scored by RECIST criteria and will not be evaluated in that manner. In this study progressive disease (PD) will be defined as residual increased metabolic PET scan in combination with expanded parenchymal opacity that retains mass-like discrete borders and extends outside the volume of lung that received at least 18 Gy.
Time frame: up to 5 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| SBRT Combined With Erlotinib | Progression-free Survival | 14.7 months |